PTC Therapeutics Inc Stock as Institutional Investors Enter

PTC Therapeutics, Inc. (NASDAQ:PTCT) Logo

Sentiment for PTC Therapeutics Inc (NASDAQ:PTCT)

PTC Therapeutics Inc (NASDAQ:PTCT) institutional sentiment increased to 2.06 in 2019 Q1. Its up 0.81, from 1.25 in 2018Q4. The ratio is positive, as 99 hedge funds increased or opened new stock positions, while 48 trimmed and sold equity positions in PTC Therapeutics Inc. The hedge funds in our partner’s database now possess: 55.24 million shares, up from 45.09 million shares in 2018Q4. Also, the number of hedge funds holding PTC Therapeutics Inc in their top 10 stock positions was flat from 3 to 3 for the same number . Sold All: 21 Reduced: 27 Increased: 64 New Position: 35.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $2.59 billion. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

The stock decreased 1.23% or $0.55 during the last trading session, reaching $44.34. About 405,252 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 30.72% since August 15, 2018 and is uptrending. It has outperformed by 30.72% the S&P500.

Axon Capital Lp holds 13.11% of its portfolio in PTC Therapeutics, Inc. for 165,800 shares. Great Point Partners Llc owns 1.81 million shares or 6.76% of their US portfolio. Moreover, Opaleye Management Inc. has 2.23% invested in the company for 213,800 shares. The Quebec – Canada-based Sectoral Asset Management Inc has invested 2.1% in the stock. Elk Creek Partners Llc, a Colorado-based fund reported 467,537 shares.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Ratings analysis reveals 100% of PTC Therapeutics’s analysts are positive. Out of 3 Wall Street analysts rating PTC Therapeutics, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $40 while the high is $61. The stock’s average target of $48 is 8.25% above today’s ($44.34) share price. PTCT was included in 8 notes of analysts from February 22, 2019. The company was maintained on Thursday, February 28 by Cantor Fitzgerald. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, March 6 report. The firm has “Buy” rating given on Friday, February 22 by RBC Capital Markets. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Tuesday, March 19 with “Buy” rating.

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Investorplace.com which released: “7 Disruptive Biotech Stocks to Buy for 2025 – Investorplace.com” on August 01, 2019, also Benzinga.com with their article: “PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients – Benzinga” published on June 07, 2019, Finance.Yahoo.com published: “Here is What Hedge Funds Think About PTC Therapeutics, Inc. (PTCT) – Yahoo Finance” on May 01, 2019. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Nasdaq.com and their article: “PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates – Nasdaq” published on August 06, 2019 as well as Seekingalpha.com‘s news article titled: “PTC Therapeutics down 9% premarket on planned equity offering – Seeking Alpha” with publication date: January 23, 2019.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.